Adjuvant Quil A improves protection in mice and enhances opsonic capacity of antisera induced by pneumococcal polysaccharide conjugate vaccines.
The adjuvant effect of Quil A on the primary antibody response of mice to pneumococcal capsular polysaccharide conjugates was examined. Quil A increased the anti-capsular polysaccharide antibody titres, the protection against Streptococcus pneumoniae, and the opsonic capacity of the antibodies as measured in a newly developed in vitro phagocytosis assay, using the mouse macrophage cell line J774.
DeVelasco
E A
EA
Eijkman-Winkler Institute of Medical Microbiology, Utrecht University, The Netherlands.
Dekker
H A
HA
Antal
P
P
Jalink
K P
KP
van Strijp
J A
JA
Verheul
A F
AF
Verhoef
J
J
Snippe
H
H
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D001428:Bacterial Vaccines / Q000276:immunology*; D002460:Cell Line; D007106:Immune Sera / Q000276:immunology; D008264:Macrophages / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D009895:Opsonin Proteins / Q000276:immunology*; D010587:Phagocytosis / Q000276:immunology; D011134:Polysaccharides / Q000276:immunology; D062605:Quillaja Saponins; D012503:Saponins / Q000494:pharmacology*; D013296:Streptococcus pneumoniae / Q000276:immunology*
D000276:Adjuvants, Immunologic; D001428:Bacterial Vaccines; D007106:Immune Sera; D009895:Opsonin Proteins; D011134:Polysaccharides; D062605:Quillaja Saponins; D012503:Saponins; C046386:Quil A